MarketPR
Abivax, the French biotech company, saw its shares soar 40% on Tuesday after releasing fresh data on its experimental lead drug for bowel disease.
The clinical update sent the stock sharply higher in a single trading session, resetting the market's view of the company's lead program in one swift move.
The Catalyst: A Fresh Clinical Data Release The move traces to one event: Abivax released new data on its experimental lead medicine, which targets bowel disease.
For a biotech whose primary drug candidate has yet to complete the regulatory approval process, clinical data is the primary signal investors have about whether the asset will eventually succeed.
Keep reading